CTI data files SPA with FDA for new pixantrone phase III trial in refractory or relapsed intense B-Cell NHL Cell Therapeutics, Inc. today announced it offers filed for a particular Protocol Assessment with the U news .S. Food and Medication Administration for the design of its new stage III trial of pixantrone for sufferers with relapsed or refractory intense B-Cell non-Hodgkin’s lymphoma . In the filing, CTI proposed to the FDA that the randomized research will review pixantrone plus rituximab against the current standard regimens used to take care of this individual group.
CT scans may damage patients’ DNA, study finds Cellular damage occurs when people undergo CT scans, but whether this causes cancer or any kind of other health problems is unclear, a fresh study finds. The use of medical imaging for cardiovascular disease has exploded previously decade, study senior writer Dr. Joseph Wu, director of the Stanford Cardiovascular Institute, stated in a Stanford information release. These exams expose patients to a nontrivial amount of low-dose radiation, Wu added. But nobody really understands just what this low-dose radiation does to the patient. We now have the technology which allows us to look at very subtle, cell-level changes.